Trial Profile

A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 20 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tivantinib (Primary)
Indications Liver cancer
Focus Registrational; Therapeutic Use
Acronyms METIV-HCC
Sponsors Daiichi Sankyo Company

Most Recent Events

03 Apr 2018 Results assessing safety and efficacy published in the Lancet Oncology
06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
17 May 2017 According to an ArQule media release, data from this strial will be presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com